This high discrimination between AD and non-AD was verified in patients with neuropathologically confirmed post-mortem tissue (AUC = 0.99) and despite all individuals been given a clinical diagnosis of probable AD during life—confirming the potential clinical utility of plasma p-tau. Here, MAPT is linked to Alzheimer disease.